Shionogi to acquire IntraBio for $2 billion

Japanese drugmaker Shionogi has agreed to acquire Austin, Texas-based biotech IntraBio for $2 billion in cash, turning it into a wholly owned subsidiary. The deal grants Shionogi global rights to Aqneursa, a drug approved for Niemann-Pick disease type C and Ataxia-Telangiectasia. The acquisition expands Shionogi's rare disease portfolio, building on its 2025 purchase of Radicava, as the company integrates IntraBio's commercial-stage assets and $68 million in 2025 sales.

Terms and financial impact of the acquisition

• ▪Under Shionogi's deal to acquire IntraBio, Shionogi will turn IntraBio into a wholly owned subsidiary of Shionogi's New Jersey-headquartered U.S. division
• ▪IntraBio reported sales of $68 million in 2025, according to a statement by Shionogi
• ▪Japanese drugmaker Shionogi agreed on October 5, 2026 to acquire Austin, Texas-based drugmaker IntraBio for $2 billion in cash

Medical applications and approvals of Aqneursa

• ▪Aqneursa, which emerged from research at the University of Oxford, combats the toxic buildup of lipids in the cells of people with Niemann-Pick disease type C
• ▪Through the acquisition of IntraBio, Shionogi will acquire global rights for Aqneursa, a marketed treatment approved for two inherited disorders
• ▪In a clinical trial, the use of Aqneursa was associated with improved patient scores on an evaluation of movement disorders in people with Niemann-Pick disease type C
• ▪Aqneursa won U.S. approval in 2024 for Niemann-Pick disease type C, and secured a second clearance in September 2026 for Ataxia-Telangiectasia

Shionogi's drug portfolio and expansion

• ▪Shionogi is currently conducting a Phase 3 trial of its experimental treatment for Fragile X syndrome, which it acquired through a 2020 buyout of Tetra Therapeutics
• ▪Shionogi's acquisition of IntraBio is intended to expand Shionogi's rare disease business, which was launched with the acquisition of the ALS drug Radicava from Tanabe Pharma in 2025
• ▪Shionogi's U.S. portfolio includes the COVID-19 medicine Xocova and a treatment for complicated urinary tract and hospital-acquired respiratory infections

Debatable claims

• ▪Pharmaceutical companies should prioritize rare diseases over widespread public health conditions
• ▪Private commercialization of university-developed drugs is necessary to bring them to market